Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC)
Hielke J. Meulenbeld(Erasmus MC), Ronald de Wit(Erasmus MC Cancer Institute), Young E. Whang(University of North Carolina at Chapel Hill), Karl Heath(Merck & Co., Inc., Rahway, NJ, USA (United States)), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Xiaoyun Li(Nanjing University), Gary R. Hudes(Community Health Center), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Anthe S. Zandvliet(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scott T. Tagawa(Cornell University)
Cited by 22
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k